Sector News

Boehringer nabs oncolytic virus option deal with Austrian startup

September 29, 2016
Life sciences

Boehringer Ingelheim is making a bid in oncolytic viruses in a deal with preclinical ViraTherapeutics that’s worth up to €210 million ($236 million). As part of the deal, the pharma gains the right to buy the biotech after Phase I development is finished.

The partners will work together to develop a next-gen oncolytic virus therapy platform–as well as to advance ViraTherapeutic’s lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other treatements.

Boehringer is already an investor in ViraTherapeutics via its venture fund. EMBL Ventures is also an investor in the biotech, which remains responsible for the preclinical and clinical testing of VSV-GP through Phase I.

“VSV-GP has demonstrated the ability to prime and boost an anti-cancer immune response and does not appear to prompt effective antiviral immune responses,” said scientific founder and CEO Dr. Dorothee von Laer in a statement. “These properties are expected to allow ground-breaking applications of this novel treatment approach.”

The biotech plans to continue exploring the candidate’s potential to be armed with therapeutic genes, as well as antigens, for use as a prophylactic or therapeutic vaccine vector.

VSV-GP is expected to be effective against a broad range of cancers. It has a shorter replication time than other oncolytic viruses in development, according to the company. VSV-GP also doesn’t integrate into the DNA and has been modified to avoid neural inflammation associated with wild-type viruses. In the candidate, the Vesicular Stomatitis Virus has been replaced by the glycoprotein of the Lymphocytic Choriomeningitis Virus (LCMV) to hide the virus from the immune system.

“Oncolytic viruses are among the most promising new therapy approaches in cancer research and the technology developed by ViraTherapeutics may offer significant advantages compared to others currently under development,” said Boehringer Ingelheim board member Dr. Michel Pairet.

He concluded: “The new collaboration is an example of Boehringer Ingelheim’s increasing focus on partnering and further complements the company’s growing immune-oncology pipeline that includes among others, a therapeutic cancer vaccine and next generation checkpoint inhibitors.”

By Stacy Lawrence

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.